Investors can speculate about the future of a stock by watching how its insiders buy and sell stocks. Cytokinetics Inc shares valued at $72,680 were sold by Malik Fady Ibraham on Aug 05 ’25. At $36.34 per share, Malik Fady Ibraham sold 2,000 shares. The insider’s holdings dropped to 140,610 shares worth approximately $4.94 million following the completion of this transaction.
Also, Blum Robert I sold 5,000 shares, netting a total of over 182,250 in proceeds. Following the sale of shares at $36.45 each, the insider now holds 388,108 shares.
Before that, Malik Fady Ibraham had sold 2,000 shares from its account. In a trade valued at $74,940, the EVP Research & Development traded Cytokinetics Inc shares for $37.47 each. Upon closing the transaction, the insider’s holdings decreased to 2,000 shares, worth approximately $4.94 million.
Analysts at Barclays started covering the stock with ‘”an Overweight”‘ outlook in a report released in late April. As of February 07, 2025, Citigroup has initiated its “Buy” rating for CYTK. Earlier on January 22, 2025, Stifel initiated its rating. Their recommendation was “a Buy” for CYTK stock.
Analyzing CYTK Stock Performance
On last trading session, Cytokinetics Inc [NASDAQ: CYTK] plunged -2.82% to $35.14. The stock’s lowest price that day was $34.57, but it reached a high of $35.905 in the same session. During the last five days, there has been a drop of approximately -2.87%. Over the course of the year, Cytokinetics Inc shares have dropped approximately -38.50%.
Is Cytokinetics Inc subject to short interest?
Stocks of Cytokinetics Inc saw a sharp rise in short interest on 2025-07-15 jumping by 1.92 million shares to 15.93 million. Data from Yahoo Finance shows that the short interest on 2025-06-13 was 14.01 million shares. A jump of 12.08% in short interest reflects a negative sentiment towards the stock. Despite the fact that short shares comprise just 10.75 of the overall float, the days-to-cover ratio (short ratio) jumped to 10.75.
Which companies own the most shares of Cytokinetics Inc (CYTK)?
In terms of Cytokinetics Inc share price expectations, FactSet research, analysts set an average price target of 61 in the next 12 months, up nearly 68.69% from the previous closing price of $36.16. Analysts anticipate Cytokinetics Inc stock to reach 67 by 2025, with the lowest price target being 55. In spite of this, 12 analysts ranked Cytokinetics Inc stock as Buy at the end of 2025. On November 08, 2024, RBC Capital Mkts assigned a price target of “an Outperform” to the stock and initiated coverage with a $80.
